ASH 2019: Carfilzomib, Dexamethasone, and Daratumumab Triplet Offers Benefits in Relapsed/Refractory Multiple Myeloma
Outcomes are superior when compared with carfilzomib and dexamethasone alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.